COVID SCIENCE: Pollen level in air linked to COVID-19 rates

11/03/2021 3:50:00 AM

Covıd 19, Coronavirus

COVID SCIENCE: Pollen level in air linked to COVID19 rates

Using data from 130 sites in 31 countries, researchers found that airborne pollen levels, sometimes in combination with humidity and temperature, accounted for up to 44% of the variability of COVID-19 infection rates during the spring of 2020. The effect was not connected with pollen allergies, the researchers said. 

"As we cannot completely avoid pollen exposure, we ... encourage high-risk individuals to wear particle filter masks during high pollen concentrations," said coauthor Athanasios Damialis of Technical University of Munich, in Augsburg, Germany. 

Read more:
ABS-CBN News »

Regeneron says its COVID-19 antibody cocktail helps prevent symptomatic COVID-19New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said. investing with maria D bate was the best thing that have ever happened to me cause I ear u p to $5000 with $400 through forex trading she's the best I know of , after I was scammed , thanks very much mam . well if you are interested click and message her 👇👇👇 mariadbates2

Court of Appeals has 18 active COVID-19 cases; suspends work March 19The Court of Appeals (CA) has decided to suspend work on Friday, March 19, for a “more thorough disinfection, cleaning and sanitation” of its offices on Maria Orosa Street in Ermita, Manila due to 18 active cases of corona virus diseases 2019 ( COVID-19 ) infections among employees. 💕SP0TIFY PREMIUM SOLO 1 month- 15 PESOS 2 months - 30 PESOS 3 months- 45 PESOS 4 months- 55 PESOS 6 months- 65 PESOS 8 months- 75 PESOS 12 months- 95 PESOS FAMHEAD 1 month- 48 PESOS 2 months- 55 PESOS 3 months- 70 PESOS 6 months- 100 PESOS 8 months- 130 PESOS 12 months- 170 P VIU* PREMIUM PRICES: 14 DAYS- 15 pesos 1 MONTH - 35 pesos 6 MONTHS- 75 pesos 12 MONTHS- 100 pesos 💌 me if you want to be a reseller❣️ 🌹 N3TFLIX PREMIUM 🌹 NO HOLD/WIPE 1 MONTH Shared- 75 Solo- 250 pesos 2 MONTHS Shared- 150 pesos Solo- 400 pesos 3 MONTHS AND 20 DAYS Shared- 170 Solo- 660 4 MONTHS AND 20 DAYS Shared- 240 Solo- 800 6 MONTHS AND 20 DAYS Solo- 370 Shared- 1200 Longer subs also available.

2 more COVID-19 deaths, 19 new cases among Filipinos abroad—DFAThe Department of Foreign Affairs (DFA) on Saturday, March 20, reported that two more overseas Filipinos succumbed to the deadly coronavirus disease, bringing the total number of fatalities to 1,047.

DFA: 19 more Filipinos abroad sick with COVID-19, 2 new deaths recordedMANILA - The Department of Foreign Affairs (DFA) recorded 19 more Filipinos abroad infected with COVID-19 , with 2 additional deaths. Thank God for bringing bitcoin to man,it has being a great source of blessing to all of man kind who have passion for bitcoin trading. Now the poor are getting rich over night and the rich getting richer. SamuelEddiy thank you for your proper management .

Gov’t media COVID-19 cases climb to 274; PTV active cases down to 19The number of people who got the coronavirus disease ( COVID-19 ) in the government's different media platforms climbed to 274 on Saturday, based on the latest count of the Presidential Communications Operations Office (PCOO).

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.endIndex: (CNN) -- New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said Monday.The suspension of work was recommended by Associate Justice Ramon R.The number of foreign-based Filipinos who have contracted COVID-19 is now at 15,967, as 19 new positive cases were also recorded.

Pollen levels linked to COVID-19 rates Higher pollen concentrations in the air have coincided with increases in COVID-19 infection rates, a large study shows, suggesting a possible link.  Using data from 130 sites in 31 countries, researchers found that airborne pollen levels, sometimes in combination with humidity and temperature, accounted for up to 44% of the variability of COVID-19 infection rates during the spring of 2020. In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release. The effect was not connected with pollen allergies, the researchers said. Garcia said the disinfection, cleaning the sanitation will be done until Sunday, March 21.  In a report published on Monday in the Proceedings of the National Academy of Sciences of the USA, they explained that in everyone, exposure to pollen reduces the ability of the respiratory tract lining to defend itself against viruses by diminishing the release of the antiviral protein interferon. Each participant received one dose of the drug or a placebo, which does nothing, administered as an injection through the skin.  The study also reports that under similar pollen concentrations, infection rates were halved when lockdown measures were in place, because the lockdowns limited exposure to both the virus and the pollen that diminishes the immune response.75 percent, while fatality rate remain at 6.

  "As we cannot completely avoid pollen exposure, we . The drug provided 72% protection against symptomatic infections in the first week and 93% protection in subsequent weeks, Regeneron said.  There are CA offices in Cagayan de Oro City for Mindanao and in Cebu City for the Visayas... Those who received the antibody cocktail and experienced a symptomatic infection resolved their symptoms in one week, the company said, compared to three weeks among those who received a placebo. encourage high-risk individuals to wear particle filter masks during high pollen concentrations," said coauthor Athanasios Damialis of Technical University of Munich, in Augsburg, Germany.  Watch more in iWantTFC Robust vaccine responses seen during pregnancy and lactation Pregnant and lactating women who received the mRNA vaccines from Pfizer/BioNTech or Moderna had immune responses similar to those seen in non-pregnant, non-lactating women, a new study found. Myron Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network and is the director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a statement.

  In all cases, the COVID-19 antibodies induced by the vaccines were transferred to the babies via the placenta or breast milk, according to a report published on Monday on medRxiv ahead of peer review. The researchers studied 84 pregnant women, 31 breastfeeding women, and 16 non-pregnant women who received the vaccines." Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said.  Immune responses were equivalent in all three groups, and all three groups had higher antibody levels than another group of 37 women who were infected with the coronavirus while pregnant.  "Dampened response to vaccination has been noted in the past for other vaccines in pregnancy," said coauthor Galit Alter of the Massachusetts General Hospital in Boston. None of the four deaths in the trial -- two among those who received the drug and two who received a placebo -- were due to COVID-19 or the drug.  She added that the study addressed an important question as COVID-19 vaccines are rolled out, given that there is currently "limited to no data on how they work in this population.

"  Pregnant and lactating women were not included in initial COVID-19 vaccine trials. The drug is currently authorized to be administered as an IV, which takes longer and may be part of the reason why uptake of the treatment has been limited. A study testing the Pfizer/BioNTech vaccine in pregnant women got underway last month.  Rapid test can screen for variants of concern A new test can rapidly screen thousands of nasopharyngeal swab samples for the concerning, more contagious new virus variants first identified in the UK, South Africa and Brazil, researchers said. A single shot reduced the risk of progressing to symptomatic COVID-19 by 31% overall. Watch more in iWantTFC The test uses probes that change color at different temperatures depending on whether it detects a specific mutation, called N501Y, that is present in all three variants. The test, for now, is not capable of differentiating between them, so positive samples would need further testing to identify the particular variant, said David Alland of Rutgers University in New Jersey, coauthor of a report posted on Monday on medRxiv ahead of peer review. Participants received the treatment or a placebo, and the trial showed that the duration of symptoms was shortened and viral levels were reduced in those who received the antibody cocktail.

  "Our next job, already mostly completed, will be to add to the test so that a second mutation .. However, the US government said last month it will no longer distribute bamlanivimab for use on its own because of a sustained increase in coronavirus variants in the United States.. called E484K, can also be detected," he said. So far, Regeneron's cocktail has been shown to be effective against coronavirus variants of concerns. "This will distinguish variants .

.com,.. from the UK from those of South African or Brazilian origin."  The test should continue to detect these variants of concern even if the virus continues to mutate, he said. In those cases, the temperature at which the probes change color will be altered, and any unforeseen color change will flag a sample as likely containing a new mutant, Alland said.

  The assay is open-source, so it can be updated by the Rutgers researchers or other teams.  Antibody combo treatment protects against severe COVID-19 A combination of two monoclonal antibody drugs – bamlanivimab and etesevimab - from Eli Lilly and Co reduced the risk of hospitalization and death by 87% in a U.S. study of 769 non-hospitalized COVID-19 patients with risk factors for developing severe illness, according to trial data released by the company on Wednesday.  This is the second late-stage, randomized trial to show that the antibody cocktail is effective at treating mild-to-moderate COVID-19.

  The previous study, published in January, used a higher dose of the drugs and reduced the risk of hospitalization by 70%. U.S. regulators authorized the combination therapy in February for use in COVID-19 patients age 12 and over who are not yet hospitalized but are at high risk for developing serious complications. European regulators authorized its use in March.

  "We have few other diseases where we have drugs that can offer this magnitude of benefit," said Daniel Skovronsky, chief scientific officer at Eli Lilly.  (Reporting by Nancy Lapid; Additional reporting by Michael Erman and Carl O'Donnell; Editing by Bill Berkrot) .